Strategic Partners

Celimmune has in-licensed AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease II (RCD II) from Amgen (NASDAQ:AMGN).

AmgenLogo

More details about Celimmune’s AMG 714 license transaction can be found at www.amgenbd.com.

We count on the support of a trusted network of collaborators, including:

2LPharma

2L_Pharma

www.2Lpharma.com

Biomedal, S.L.
Biomedal

www.biomedal.com